Michael Young is co-founder and co-CEO of Lindus Health, an AI-native contract research organisation that runs clinical trials end-to-end and has begun licensing therapeutics to take through trials itself. A former special adviser in the Home Office and 10 Downing Street, where he worked on the UK Life Sciences Strategy, Michael joined Adam and Rafi to explain why running trials, not discovering drugs, has become the biggest bottleneck in medicine. He unpicks the incentives that keep contract research slow and expensive, reflects on Kate Bingham and the Vaccine Taskforce, describes how Lindus can now run five drug programmes for the cost of one a decade ago, and looks ahead to a wave of AI-discovered drug candidates the current system cannot absorb. He closes with a practical ask of every listener: sign up for a clinical trial.